Active Filter(s):
Details:
With the acquisition of Teralithe 250mg, divisible tablet and Teralithe LP 400mg, prolonged-release tablet (lithium carbonate), by Laboratoires DELBERT reinforces the strategy to ensure safe and continuous availability of Medications to patients and reinforce CNS portfolio.
Lead Product(s): Lithium Carbonate
Therapeutic Area: Psychiatry/Psychology Product Name: Teralithe
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires DELBERT
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 25, 2022